Drug DevelopmentEtripamil has shown promising results, meeting the primary endpoint in the ReVeRA study and demonstrating a rapid median time to maximum effect, indicating its potential as a fast-acting treatment option.
Financial HealthMilestone has a robust financial position with sufficient cash reserves to fund its operations well into the future, which is further bolstered by the expectation of a substantial synthetic royalty payment under an existing agreement.
Regulatory MilestoneWith the FDA not requesting additional trials for etripamil, the regulatory pathway seems smoother, and the company is poised to resubmit a New Drug Application, setting the stage for potential approval and market launch.